USMJ Brand Prominence Bolstered By DEA Reclassification Of CBD
September 28 2018 - 09:02AM
InvestorsHub NewsWire
Dallas, TX -- September 28, 2018 --
InvestorsHub NewsWire -- North American Cannabis Holdings (USOTC:
USMJ) (“USMJ”) today revealed details regarding an enthusiastic
shareholder response to news that the DEA, in cooperation with the
FDA, had rescheduled some applications of cannabidiol (CBD)
reducing previous restrictions. The DEA announced yesterday
that drugs including “finished dosage formulations” of CBD approved
by the FDA containing THC below 0.1% will be considered Schedule 5 drugs. After advancing a
number of cannabis sector initiatives since 2013, USMJ has recently
announced a reorganization to leverage its “USMJ” brand
name by launching a comprehensive online portal selling
cannabis related products while positioning its existing AmeriCanna
Cafe restaurant business unit for accelerated growth by spinning it off into a standalone listing where
USMJ shareholders receive a dividend of spinoff stock. USMJ
anticipates announcing a spinoff transaction within the next two
weeks. The increased number of calls and emails in reaction
to the recent DEA and FDA news communicated an eager enthusiasm for
USMJ to take its next steps with the ecommerce site and AmeriCanna
Cafe businesses. USMJ has built nearly $1 million in cannabis
sector sales since 2013 and already executed one spinoff, Puration,
Inc. (USOTC: PURA), a cannabis infused beverage business built
around a patented cannabis extraction process.
“The DEA news today rescheduling some
applications of CBD is good news for USMJ and the pending launch of
its online portal and independently listed AmeriCanna Café,” said
Steven Rash, CEO of USMJ. “Given the market enthusiasm for the
cannabis sector generated by the DEA news, we anticipate garnering
even more attention now for our USMJ ecommerce site than originally
expected when we launch in the coming weeks.”
Learn
more at www.growusmj.com.
Disclaimer/Safe
Harbor:
This news release
contains forward-looking statements within the meaning of the
Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any disease.
Steven
Rash
CEO
North American Cannabis Holdings, Inc.
info@aciconglomerated.com
+1-800-861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2023 to Mar 2024